Ethos Technologies Inc.

Ethos Technologies Inc.

NNASDAQ:LIFE
33.99
USD
+0.73
(+2.19%)
-1.92EPS
2.18BMarket Cap
Mar 03Next Earn
Ethos Technologies Inc.
NASDAQ:LIFE
(Nasdaq Stock Market)

Recent

price

33.99

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
TTM
USD
2.55
4.08
6.2
12.21
Revenue per Share
0.03
0.78
1.14
-1.97
Basic EPS, GAAP
-0.67
-0.25
0.48
1.74
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
-2.54
-1.71
-0.39
7.88
Book Value per Share
-2.58
-1.75
-0.43
7.84
Tangible Book Value per Share
63
63
63
60
Basic Weighted Avg Shares
160
255
388
728
Sales/Revenue/Turnover
-1.82
19.12
18.81
-16.06
Operating Margin (%)
6
5
6
7
Depreciation Expense
2
49
71
-118
Net Income, GAAP
25.76
9.46
6.06
- -
Effective Tax Rate (%)
1.06
19.16
18.36
-16.16
Profit Margin (%)
122
107
133
131
Working Capital
- -
2
1
1
LT Debt
-159
-107
-24
512
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-37.56
-117.39
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
64
65
Market Capitalization
704
1,157
2,182

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
259
302
408
Cash, Cash Equivalents & STI
145
168
221
Accounts Receivable, Net
80
88
117
Inventories
- -
- -
- -
Total Current Liabilities
155
199
277
Payables & Accruals
132
154
198
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-77.49%
Free Cash Flow
- -
- -
-293.31%
Net Income, GAAP
- -
- -
45.71%
Sales/Revenue/Turnover
- -
- -
52.05%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
67
255
2025
95
89
94
110
388
2026
193
190
235
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.15
0.78
2025
0.2
0.3
0.25
0.39
1.14
2026
-3.46
0.31
0.07
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
aTyr Pharma, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of medicines based on novel biological pathways with a focus on tRNA synthetase biology. The company develops protein-based therapeutics targeting fibrosis and inflammation, primarily through its lead product candidate efzofitimod (ATYR1923), a first-in-class biologic immunomodulator that selectively modulates neuropilin-2 (NRP2) to resolve aberrant inflammation and potentially prevent fibrosis progression, particularly for interstitial lung diseases such as pulmonary sarcoidosis. Additional product candidates include fusion proteins derived from domains of aspartyl-tRNA synthetase (ATYR0101) and alanyl-tRNA synthetase (ATYR0750), with the latter being a novel ligand for fibroblast growth factor receptor 4 (FGFR4). The company also engages in collaborations and license agreements, notably with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan, expanding its reach in Asian markets. Founded in 2005 and headquartered in San Diego, California, aTyr Pharma is advancing its drug pipeline through clinical trials and strategic partnerships. Recently, aTyr Pharma experienced a setback when its global pivotal Phase 3 EFZO-FIT study in pulmonary sarcoidosis failed to meet the primary endpoint related to the reduction in mean daily oral corticosteroid dose at week 48. Following these results announced in September 2025, the company initiated discussions with the FDA to determine the path forward. Despite this, aTyr continues to raise capital, having secured approximately $18.8 million subsequent to Q4 2024, and maintains ongoing collaborations and research efforts, including partnerships valued at $50 million in 2023 with biotech firms and academic institutions. The company’s strategic focus remains on advancing its therapeutic candidates, expanding patient-centric clinical programs, and leveraging collaborative alliances to enhance its portfolio and geographic presence in North America, Europe, and Asia.

Company News

  • Omega Pacific Closes First Tranche of LIFE Offering

  • SEABOURN BRINGS THE FLAVORS OF THE CARIBBEAN TO LIFE WITH NEW EARTH & OCEAN CULINARY EXPERIENCES

  • Standard Uranium Closes First Tranche of LIFE Offering

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ethos Technologies Inc. - LIFE

  • ANAVEX LIFE SCIENCES CORP. AVXL Investors with Significant Losses Encouraged to Contact Kirby McInerney LLP About Securities Class Action

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ethos Technologies Inc. - LIFE

  • GLOBE LIFE INC. DECLARES DIVIDEND

  • Ethos Technologies: Bigger Beats, Thinner Margins

  • SCENTBIRD AND DRIFT BRING THE WORLD OF THE HUNGER GAMES TO LIFE THROUGH SCENT WITH SCENTBIRD x THE HUNGER GAMES: SUNRISE ON THE REAPING COLLECTION

  • Omega Pacific Announces LIFE Offering

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ethos Technologies Inc. - LIFE

  • Ethos Technologies: High Growth At A Fair Valuation

  • Ethos Technologies Analysts Boost Their Forecasts After Upbeat Q3 Results

  • Standard Uranium Upsizes LIFE Offering

  • Ethos Technologies: 3 Key Takeaways for Long-Term Investors

  • Cizzle Brands Corporation Announces Filing of French Translation of LIFE Offering Document; Share Consolidation to Take Effect on Thursday, November 5, 2026

  • Ethos Technologies Inc. (LIFE) Q3 2026 Earnings Call Transcript

  • Ethos Technologies Inc. (LIFE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

  • What Ethos Technologies Inc. Class A Common Stock (LIFE) Said on Its Q3 Earnings Call

  • Ethos Reports Third Quarter Fiscal Year 2026 Financial Results